STOCK TITAN
  1. Home
  2. Sec-filings
  3. CDNA
  4. [Form 4] CareDx, Inc. Insider Trading Activity

CareDx Form 4: Michael Goldberg Adds Quarterly Stock Grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

On July 8, 2025, CareDx, Inc. (CDNA) director Michael Goldberg filed a Form 4 reporting receipt of 1,218 shares of common stock at a grant price of $0 under the company’s Outside Director Compensation Policy. The automatic equity award, issued in lieu of quarterly cash fees, raises his direct ownership to 154,216 shares. No open-market purchases, sales or derivative transactions were disclosed, indicating the filing is a routine governance matter rather than a signal of insider sentiment.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine director stock grant; neutral signal for CDNA.

The 1,218-share award to Director Michael Goldberg represents about 0.8% of his 154k-share stake and less than 0.003% of CareDx’s shares outstanding. Because it is an automatic quarterly grant issued at $0, the transaction does not reflect proactive insider buying or selling pressure. As such, the Form 4 is unlikely to affect valuation, liquidity, or market sentiment; it mainly satisfies Section 16 reporting requirements.

Insider Goldberg Michael
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 1,218 $0.00 --
Holdings After Transaction: Common Stock — 154,216 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Goldberg Michael
(Last) (First) (Middle)
C/O CAREDX, INC.
8000 MARINA BOULEVARD
(Street)
BRISBANE CA 94005
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/08/2025 A 1,218(1) A $0 154,216 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents an automatic quarterly grant of common stock to the Reporting Person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy.
/s/ Michael Goldberg 07/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction was reported for CDNA on July 8, 2025?

Director Michael Goldberg received 1,218 shares of CareDx common stock as an automatic quarterly equity grant.

How many CareDx shares does Michael Goldberg now own?

Following the grant, he beneficially owns 154,216 shares directly.

Was the equity grant executed under a Rule 10b5-1 trading plan?

No. The filing shows a routine compensation grant and does not reference a Rule 10b5-1 plan.

Did the Form 4 disclose any sales or derivative transactions?

No. The report lists no sales or derivative security activity.

What price was paid per share for the grant?

The shares were issued at $0 because they represent compensation, not an open-market purchase.